Stock ERFO LABORATORIO FARMACEUTICO ERFO S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Laboratorio Farmaceutico Erfo S.p.A.

Equities

ERFO

IT0005497885

Market Closed - Borsa Italiana
Other stock markets
 11:44:59 2024-07-05 am EDT 		5-day change 1st Jan Change
1.095 EUR 0.00% Intraday chart for Laboratorio Farmaceutico Erfo S.p.A. -5.60% -16.41%
Jul. 01 ITALY GROWTH WINNERS & LOSERS: Espe on top; Redfish bad AN
Jun. 04 Erfo, MIMIT grant facilities for Plants project. AN

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
LABORATORIO FARMACEUTICO ERFO S.P.A. Stock Laboratorio Farmaceutico Erfo S.p.A.
-16.41% 10.19M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.99% 320B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
B+
NOVARTIS AG Stock Novartis AG
+13.83% 220B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
A+
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
  1. Stock Market
  2. Equities
  3. ERFO Stock
  4. Ratings Laboratorio Farmaceutico Erfo S.p.A.